Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
In 2025, the FDA expanded SKYTROFA approval to include adult growth hormone deficiency, further strengthening the commercial success of the platform
An AMH level below 1.66 ng/mL suggests the ovarian reserve may be diminished
Retatrutide targets three hormone receptors simultaneously (GLP-1, GIP, and glucagon), distinguishing it from approved agents such as semaglutide (GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist)
[PMID: 170091] PubMed record related to this compound for laboratory literature review
If youre curious about how these peptides could work in a personalized protocol, consult with a provider who understands both functional medicine and performance physiology
NAC has a longer clinical track record
US$ 23.60
US$ 26.17
US$ 26.72
US$ 27.57
US$ 20.80
